MINI REVIEW article
Sec. Social Neuroscience
Volume 10 - 2019 | https://doi.org/10.3389/fpsyt.2019.00930
Oxytocin as Treatment for Social Cognition, Not There Yet
- 1Department of Pharmacology, University of the Basque Country UPV/EHU, Leioa, Spain
- 2Centro de Investigación Biomédica en Red en Salud Mental CIBERSAM, Leioa, Spain
In a short time, oxytocin has progressed from being a regular hormone involved in parturition and breastfeeding to be possibly the neuromodulator that has gathered the most attention. Attributed many positive roles in the modulation of different aspects of social behavior, such as bonding, empathy, cooperation, trust, and generosity, as well as roles as a natural anxiolytic and antidepressant, the expectations on oxytocin becoming a treatment for a number of disorders with associated social deficits have dramatically raised over the last years. However, despite the field has been investigating oxytocin’s role in social behavior for over twenty years, there are still many unknowns on oxytocin’s mechanisms of action and efficiency and the increasing number of clinical trials administering oxytocin to different clinical groups seem to disagree in its properties and report in most cases conflicting results. This has led to some disappointment among researchers and clinicians as oxytocin might not be the miraculous molecule that works in a “one size fits all” fashion initially considered. Conversely, this down-side of oxytocin might merely reflect the complexity of its neurotransmission system. The current reality is that, although oxytocin seems to have potential therapeutic value, there are key questions that remain unanswered as to decide the optimal target groups and treatment course. Here, we present an overview on critical points regarding the oxytocin system in health and disease that need to be better understood to establish its therapeutic properties and to decide who could benefit the most from its treatment.
The field of clinical behavioral neuroscience has rarely experienced such an enthusiasm for a single molecule as the one elicited by oxytocin (OXT). Over the past decade, the peptide hormone that regulates birth-related processes has been transformed into a somewhat magical neurotransmitter that modulates an individual’s social abilities. The rapidly growing field of OXT research has attributed this molecule miraculous properties as enforcer of trust, empathy, generosity, altruism, or even love, to an extent that commercially available nasal sprays are advertised to enhance an individual’s social skills. Despite many doubtful reports endorsing OXT’s power as a miracle potion, rigorous, and sound research has indeed proven the role of OXT in regulating social cognition (1–3). Thus, in the recent years, there has been an explosion in the number of clinical trials to test OXT’s efficiency in improving social deficits in a variety of conditions with associated social dysfunction including both neuropsychiatric disorders such as autism, schizophrenia, depression, social anxiety, drug addiction, as well as neurodegeneration-related disorders ranging from dementia and Huntington’s disease to ageing. Although the potential success of OXT as a pharmacotherapy is exciting, the increasing number of treatment studies report conflicting results and several issues need to be addressed before accepting the effectiveness of this molecule. Important questions such as selection of the clinical sample, dosage, timing, effect by sex, behavioral outcome measure, neurobiological effect or correlation with OXT-related biomarkers, to potentially identify best responders, have not been systematically addressed. In the present review, first we summarize important aspects of the OXT signaling system which should be considered to inform treatments; later, we present evidence linking alterations in the OXT system in neuropsychiatric disorders characterized by social dysfunction and last, we summarize results of OXT treatments in clinical trials together with an overview on critical points that need to be better understood to establish its therapeutic properties and to decide who could benefit the most from its treatment.
The Oxytocin System
Although OXT is synthesized to some extent in certain peripheral areas, the majority is produced in neurons located in the paraventricular (PVN) and supraoptic (SON) nuclei of the brain hypothalamus. It is released both to the bloodstream to modulate several peripheral functions, and within the brain, where it acts as a neuromodulator. OXT-producing neurons project to various brain areas including limbic regions, brain cortex, and brainstem (4), where they release OXT in an action potential-dependent manner. In addition, OXT, like other neuropeptides, can be released independently of action potentials by exocytosis through the whole neuron, diffusing in the extracellular space (5). An important molecular modulator of this type of release is the transmembrane protein CD38 (cluster of differentiation 38). OXT’s local release is thought to be responsible for its well-known self-priming process, in which OXT stimulates its own release in a positive feedback loop, presumably through activation of its own somato-dendritic autoreceptor (6). This is important for treatment design, as despite the short half-life reported for the peptide in brain (about 20 min), a single dose of OXT has been shown to have a behavioral effect that lasts for several hours (6). In addition to its own receptor, OXT expressing neurons also express a variety of other receptors that, when activated, can trigger OXT release. The most studied is the melanocortin 4 receptor (MC4R), and current efforts are made to develop pharmacotherapies that induce endogenous OXT release, to achieve physiological-like conditions.
The oxytocin receptor (OXTR) belongs to the G-protein-coupled seven transmembrane receptor superfamily and is located throughout the brain both in neurons and glia (7, 8). OXTR can be coupled to Gαq and Gαi/o, activating or inhibiting different intracellular signaling cascades [reviewed recently (9)]. An interesting hypothesis is that these different pathways are engaged depending on the local concentration reached by OXT. Thus, low concentrations activate Gαq whereas higher concentrations promote the activation of Gαi/o proteins (10). Further, upon continuous agonist exposure OXTR undergoes rapid and extensive internalization and desensitization, through the classical clathrin-mediated pathway (11). Such complex regulation of the OXTR signaling pathway indicates the need of dose-response studies that could inform treatment design.
Further, the existence of a critical period when OXT modulation might influence developmental processes achieving long-lasting effects, has been suggested. Seminal studies in voles have shown that early OXT administration has long-term consequences in both OXT expression in the PVN (12) and social behavior in adults (13). In fact, in rodents, the OXT system undergoes specific changes from birth throughout the lifespan: the number and complexity of OXT projecting neurons gradually increases postnatally, reaching maturity at juvenile age and the expression of OXTR also shows a specific developmental pattern (4). This precise developmental regulation of the OXT system is thought to modulate different aspects of brain development. Interestingly, in humans, a peak in OXTR binding has been observed in the ventral pallidum during early childhood in typically developing individuals, but this peak was absent in children with ASD (14). Determining whether these changes can be permanently reversed or compensated through early manipulations is still unkown.
The Oxytocin System in Psychiatric Disorders of Social Cognition
As described above, for a functional OXT system, proper production and release of OXT, together with a precise expression of OXTR is needed. Once the role of the OXT system in modulating affiliative behavior across vertebrate species was established, efforts in translating these findings to the clinic begun (15). Special emphasis has been placed on trying to identify biomarkers for disorders with altered social cognition. The most studied players within the OXT system are the OXT peptide, the OXTR and CD38, since both OXT (its synthesis, processing, storage, and release), as well as its receptor, could be affected in a pathological state. Identifying biomarkers would not only help diagnosis, but also serve as a stratifying factor to ascertain which patients could benefit the most from OXT’s treatment.
Peripheral OXT Measurements
At a biochemical level, there is still much debate on whether peripheral OXT levels (in blood, urine, or saliva) are correlated with OXT levels in brain (16). Nevertheless, studies measuring OXT concentrations in plasma in psychiatric populations show contradictory results, reporting in some cases no differences, and in others both lower as well as higher OXT levels in patients compared to controls. For example, some studies found lower plasma OXT associated with autism (17, 18), depression (19), and schizophrenia (20, 21) while other studies described higher OXT levels associated with autism (22, 23) and depression (24, 25). There are several factors that might explain some of these contradicting results. First, current methodology used to measure OXT has not been rigorously validated. Traditional immuno-assays (such as ELISA or RIA) require a sample extraction process to eliminate potentially interfering proteins that at the same time eliminates protein-bound OXT (26). Newer methods using liquid chromatography/mass spectrometry (LC/MS) separate first OXT from any bound protein, measuring total (free plus protein-bound) OXT, although the functional significance of free vs. bound OXT remains unknown (26). Thus, development and/or validation of straight-forward, sensitive, and specific assays for OXT quantification is needed. In this case, accurate measurements of OXT release into both blood and brain could be systematically monitorized and the question of whether peripheral and central OXT levels are linked, and are correlated to a given behavioral phenotype, could finally have a response.
Genetic and Postmortem Studies
Genetic studies provided converging evidence that variation in the form of single nucleotide polymorphisms (SNP) in genes within the OXT signaling system confer risk to psychiatric endophenotypes related to social dysfunction. Special attention has been drawn to the OXTR, since seminal studies performed in voles showed that the amount of parental care, affiliative bonding, and even aggression toward conspecifics, seems to be modulated by differences in the levels of OXTR expression and/or its differential distribution throughout the brain (27). In fact, in voles, genetic variation within the OXTR gene has been shown to affect OXTR density in a region-specific manner. Specifically, a certain single SNP in the OXTR gene modulated OXTR expression in the nucleus accumbens, a structure widely implicated in the processing of reward, and correlated with the propensity of the animals to form social attachments (28). However, whether this is also true for the identified human variants is uncertain, and the effect of most identified SNPs on gene expression or protein function remains to be elucidated. It is noteworthy that studies investigating the expression of the OXTR (through qPCR or receptor binding autoradiography) in postmortem brain tissue of neuropsychiatric disorders report, in most cases, a different distribution between cases and controls. For example, in individuals with autism, OXTR binding has been found to be increased in cortical and decreased in subcortical structures (14). Increased OXTR expression has been reported in the prefrontal cortex of individuals suffering from major depression (29) and alcohol use disorder (30, 31). Last, decreased OXTR mRNA was found in several brain areas of subjects with schizophrenia (32). In search for the causal factor of such differences, recent data highlight the role of DNA methylation on the transcription levels of OXTR. In fact, in mice, specific CpG sites in the promoter of the OXTR gene have been shown to be differentially methylated between brain regions expressing different levels of OXTR (33). In humans, hypermethylation of the OXTR gene was found to be associated with decreased levels of its mRNA in the temporal cortex of individuals with ASD (34). In addition to OXTR expression, few studies have investigated levels of the OXT peptide expression within the brain. As an example, subjects with major depression showed increased number of OXT-immunoreactive neurons in the PVN of the hypothalamus (35). Current research aims at ascertaining the endogenous, pharmacological, and environmental factors regulating OXT/OXTR expression.
Oxytocin in Clinical Trials
OXT administration has been tested to improve social cognition in a variety of clinical groups, including autism, depression, schizophrenia, drug addiction, and neurodegenerative disorders. However, clinical trials have yielded inconclusive results, with some reports supporting a significant positive effect and others suggesting a null effect. Several meta-analyses have been performed to address this issue (summarized below), which albeit still inconsistent, highlight the differences that might account for this inconsistency, such as the clinical sample studied, which differ in the social behavioral domain affected, and the specific outcome of social cognition being evaluated (see below section “oxytocin treatments, things to consider”).
One of the main limitations of conjunctly analyzing the data in a meta-analysis is in fact the huge variability in the outcome measure used in each study. Regardless, most studies include affective tests, such as emotion recognition and expression of emotions, as well as theory of mind as the main social behavior measures. Still, meta-analyses focusing on these common parameters show contradicting results. For example, Keech et al. co-analyzed 17 studies including individuals with autism, schizophrenia, and Prader-Willi syndrome and found no effect on emotion recognition, a trend in emotion expression, and a significant effect on theory of mind (36). However, another study that included 15 reports on a different clinical population (i.e. autism, borderline personality disorder, depression, schizophrenia, and drug dependence), found that OXT did not significantly influence any of the same behavioral outcomes (37). These differences might be due to the specific clinical populations included in each work, as another study covering 19 clinical trials including individuals with autism, social anxiety, postnatal depression, obsessive-compulsive disorder, schizophrenia, borderline personality disorder, and post-traumatic stress, showed that only the autism group presented a significant effect on social parameters (i.e. emotion recognition) (38), indicating that studies focused on a specific diagnosis, with a common behavioral domain affected, could be helpful. In fact, in a quantitative meta-analysis of 16 fMRI studies of i.n. OXT treatments in autism, borderline personality disorder, depression, social anxiety, and post-traumatic stress disorder, OXT was found to have diagnosis-specific neurobiological effects, increasing dorsal anterior cingulate activity in ASD and decreasing amygdala activity in social anxiety disorder (38). Still, a meta-analysis focusing specifically on ASD found no significant behavioral effect of OXT in neither the social nor the repetitive behavior domain (39). With respect to studies focusing specifically on schizophrenia, it is important to mention that the great majority of clinical trials have focused on positive (delusions and hallucinations) and/or negative (diminished motivation, social functioning, and ability to express emotions) symptoms as a whole, and few studies evaluated specifically social cognition outcomes. In general, no improvement of negative symptoms in schizophrenic patients has been reported (40). However, when focusing specifically on social cognition, a significant effect in outcomes for high-level social cognition (such as mentalizing and theory of mind) has been found (41). In borderline personality disorder, OXT had a beneficial impact on recognition and discrimination of emotions and on hypervigilance toward social threats, whereas it could hinder trust and cooperation (42). Recent studies are currently examining OXT’s potential beneficial effects on social cognition in conditions other than psychiatric disorders. In fact, if we assume that OXT modulates certain aspects of social cognition, it is reasonable to think that it does so regardless of diagnosis and/or condition. Thus, OXT could potentially improve the processing of emotional faces in neurodegenerative diseases such as Huntington’s disease (43) and frontotemporal dementia (44, 45). Further, OXT is currently being tested as treatment of social cognitive difficulties shown by healthy ageing individuals (46), where OXT does seem to improve certain aspects of social cognition (i.e. theory of mind), although not specifically in ageing population. Additional studies stratifying cases by the affected behavioral domain, rather than diagnosis per se, and with a common behavioral outcome are needed to ascertain OXT’s role in improving certain domains of social behavior (see below).
Oxytocin Treatments, Things to Consider
As noted from the studies above, the effectiveness of OXT in improving social cognition is still at debate. Several issues such as selection of the clinical sample, dosage, timing, effect by sex and/or age, and the choice of behavioral outcome measure could be responsible for contrasting results among trials. Further, the associated neurobiological effect or correlation with OXT-related biomarkers, to potentially identify best responders, have not been systematically addressed. Below we present the main gaps that need to be filled in order to finally attribute OXT its potentially therapeutic effect.
Although the number of human studies testing OXT’s efficacy in several disorders keeps increasing, the sample size is in most cases small and studies are underpowered. The outcome measures are also very diverse, which limits the possibility of conjunctly analyzing the data in a meta-analysis, as described above. Also, the clinical phenotype of the patients must converge in the affected social-behavioral domain, since even in the case of a common diagnosis, the clinical heterogeneity among the affected individuals is usually big. It might be worth focusing on an affected behavioral domain, rather than diagnosis. Also, the general status of the patients must allow for improvements in the behavioral outcome to be measured, ensuring that the presence of associated symptoms does not obscure interpretations of social cognition. In addition, the potential different effects based on age and sex are usually not considered. Female subjects may respond differently to OXT treatments because of potential differences in basal levels of OXT or differential expression or distribution of OXTR, since sex hormones are known to modulate the OXT system. Specifically, estrogen has been shown to regulate the expression of OXTR in brain (47). Last, the mainly postnatal development of the OXT system, as described above (48), suggests that during this early-life temporal window the OXT system might be more susceptible for long-lasting physiological and behavioral effects.
A primary issue in designing randomized clinical trials is to establish the outcome measure that defines improvement in impaired behaviors. As disorders diagnosed by behavioral evaluation, performance in a certain behavioral task affected in the disorder, a clinical interview or questionnaire, or even self-report are usually the parameters measuring treatment effectiveness. Albeit some common behavioral measurements are used, such as specific affective tests, the published outcome measures for OXT trials are, in general, very variable, with numerous non-standardized assessments. Thus, OXT has been shown to improve social cognition in many different ways, such as comprehension of affective speech in ASD (49) and facial emotion recognition in depression (50), where participants have to infer emotion from read-aloud sentences or pictures of faces, respectively. Understanding of indirect cues and recognition of social faux pas (i.e. a behavior not socially accepted) have been reported to be improved by OXT in schizophrenia (51), and improved eye contact during a social challenge has been reported in social anxiety (52). Attempts at developing standardized protocols to score improvements in social behavior over the course of a randomized clinical trial are needed.
Most trials performed to date show a great inconsistency in their treatment course, with varying doses ranging from 8 to 50 IU, which could explain the discrepancy in some of the results, particularly if different OXTR signaling pathways could be activated depending on the dose, as described above (10). Even if 24 IU has been the dose most studied to date, a much lower OXT dose of 8 IU has also been found to influence social cognition (53). Therefore, it is clear that the effects of i.n. OXT need proper dose-response studies in order to find the optimal effective dose on biology (see below) and behavior. A recent OXT acute dose/response (8–84 IU) study in schizophrenia using neurophysiological (EEG) measurements of social processing has suggested that OXT would produce biological effects in an inverted U-shaped manner, where only mid-range doses produce an effect (54). Besides, the majority of clinical trials administered an acute, single-dose OXT, and there are very limited studies investigating the effects of chronic OXT administration over a period of several months (55, 56).
Oxytocin Administration, Crossing the Blood Brain Barrier
Despite animal studies showing that systemically administered OXT shows behavioral and even neurological effects (57, 58), it is still at debate whether peripherally administered OXT crosses the blood-brain barrier in appreciable amounts (59). I.n. OXT administration has been proposed as an alternative pathway to bypass this penetrance issue (60). Still peripherally administered OXT might indirectly, through afferent feedback signals from the periphery, stimulate endogenous release within the brain (61). Studies measuring OXT cerebro-spinal fluid (CSF) levels after i.n. administration have generally shown an increase, but with some contrasting results in terms of the temporal profile. In humans, elevated CSF and blood OXT concentrations upon i.n. administration have been reported, with a relatively modest and slower increase in CSF and a much greater and more rapid increase in plasma (61). Similar results were obtained in macaques, but in this study the increase in CSF was detected more rapidly than in the previous one (62). Interestingly, another study in macaques also detected elevated OXT CSF concentrations after i.n. aerosolized administration, but not after i.n. spray or intravenous administration (63). Comparable findings were also observed in mouse and rat brain microdialysates, identifying differential temporal profile after i.n. or intraperitoneal administration (64). The criticism that some authors have raised against these results is that only modest increases in CSF levels are observed, with approximately 0.05% of intranasally administered OXT reaching the CSF within 1 hour (59). Recent studies using labeled molecules add evidence in favor of OXT’s penetrance into the brain. A study in macaques using a novel sensitive and specific quantitative mass spectrometry assay that distinguishes labeled (deuterated) from endogenous OXT, demonstrated CSF penetrance of exogenous deuterated OXT after both i.n. and intraventricular administration. Besides, this report also suggests that peripheral administration does not stimulate central release of endogenous OXT, as its level was not changed (65). Furthermore, using a novel peptide tracer for PET imaging of OXTR, the direct nose-to-brain uptake in vivo has also been recently demonstrated in rodents (66). Still, even if we accept that i.n. administered OXT reaches the brain, as animal studies seem to indicate, in what concentration, or whether the effect is due to a concomitant increase in peripheral OXT is not known. Further data on this regard would greatly inform dosing studies.
Peripheral supraphysiological OXT levels that may be achieved due to exogenous administration could produce undesirable responses and secondary central effects. Indeed, i.n. OXT administration has been shown to produce a marked acute increase in OXT plasma levels that has an elimination half-life of approximately 30 min (67). Several studies have conducted safety measurements in clinical trials supporting OXT's safety. Thus, a daily treatment with 40 IU of i.n. OXT for 4 months in schizophrenia patients did not affect OXT and vasopressin basal plasma levels, nor cardiovascular, body fluids, and food intake parameters (68). Further, several meta-analysis have characterized the side-effect profile of single dose and long-term i.n. OXT and the results support OXT as well tolerated and safe, side-effects not differing between OXT and placebo (69, 70). However, safety should be further evaluated including larger groups, and focusing on sex, age, dosing, and treatment course and also studying putative side-effect that might occur longtime after treatment.
Albeit the still unknown detailed pharmacokinetics of i.n. OXT, functional imaging studies in humans strongly support its neurological effect in brain areas involved in emotion and social cognition, as previously mentioned (71, 72). Specifically, a precise activation pattern of interconnected brain regions seems to be the basis for the behavioral effects observed with OXT (71, 73). However, clinical trials usually perform solely a behavioral readout, not always standardized (discussed above), to ascertain the effectiveness of OXT treatment, without any correlation with a biological effect. Very limited studies include functional data (such as fMRI) in combination with performance in social cognition tasks. Understanding the effect of OXT administration on brain function would greatly inform dosing and efficacy of treatment.
Correlation With OXT Biomarkers
In addition to functional measures, treatment efficacy should be considered in relation to individual differences in their specific molecular signature of the OXT system. As described above, genetic and epigenetic variation in genes within the OXT pathway correlate with endophenotypes related to social cognition. Future trials aimed at deciphering the efficacy of OXT should consider analysis at both the biological and phenotypic level. In this way, we may be able to distinguish between individuals who respond to OXT treatment (OXT responders) and those who do not (OXT non-responders), possibly based on differences in their specific endogenous OXT activity.
Oxytocin presents an exciting pharmacological treatment for improving social cognition in a variety of psychiatric disorders. It is easily administered, cost-effective, and with possibly minimal adverse effects. In the recent years, there has been an explosion in the number of clinical trials, mainly in psychiatric populations but also in other conditions affected by social deficits, to test OXT’s efficiency in improving social dysfunction. However, there are still major gaps in this area of research. Although the role of OXT in the modulation of social behavior is today indisputable, the field of OXT-based pharmacotherapy is filled with many small trials that report incongruent results. There are several matters that have not been systematically addressed when designing clinical trials that are critical to inform treatments. The integration of data from imaging, genetic, and neuroendocrine biomarkers, in conjunction with standardized evaluation of social behaviors, including longitudinal follow-ups, are required to understand the effectiveness of OXT and who could benefit from its treatment (Figure 1). In addition, there may be alternative means of manipulating the central OXT system to gain efficacy and selectivity, including more efficient i.n. delivery paradigms, or the development of small molecule agonists, positive allosteric modulators or functional selective ligands, activating a specific G protein signaling pathway (10). Endogenous OXT release could also be stimulated pharmacologically to achieve more physiological-like conditions; for instance, MC4R agonists potentiate central OXT release (74) and rescue social deficits in a mouse model of autism (75). In all, OXT has a great potential to ameliorate social dysfunction in a broad range of psychiatric disorders. Efforts should be made to understand its neurobiological mechanism of action and effect based on individual variability in underlying neuropeptide biology.
Figure 1 Schematic representation of the strategies needed to guide OXT-based treatments. Bigger sample sizes as well as studies focusing on the potential differential effect of OXT based on sex and age are needed. More efficient delivery paradigms, including the development of specific OXTR modulators would overcame the issue of i.n. administration. The integration of data from multiple aspects, including brain imaging, genetic, and neuroendocrine biomarkers, in conjunction with standardized evaluation of social behaviors, including longitudinal follow-ups, are required to understand the effectiveness of OXT and who could benefit from its treatment.
AE and OP contributed equally in drafting the manuscript and adding critical information in the different sections.
This work was funded by the Spanish Ministry of Science, Technology and Research, the Spanish State Research Agency and European Regional Development Fund (MCIU/AEl/FEDER, UE) grants RTI2018-101427-B-I00 to OP and RTI2018-094414-A-I00 to AE.
Conflict of Interest
The authors declare that this manuscript has been prepared in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
4. Grinevich V, Desarménien MG, Chini B, Tauber M, Muscatelli F. Ontogenesis of oxytocin pathways in the mammalian brain: late maturation and psychosocial disorders. Front Neuroanat (2015) 8:194. doi: 10.3389/fnana.2014.00164
5. Tobin V, Leng G, Ludwig M. The involvement of actin, calcium channels and exocytosis proteins in somato-dendritic oxytocin and vasopressin release. Front Physiol (2012) 3:261. doi: 10.3389/fphys.2012.00261
8. Dal Monte O, Piva M, Anderson KM, Tringides M, Holmes AJ, Chang SWC. Oxytocin under opioid antagonism leads to supralinear enhancement of social attention. Proc Natl Acad Sci U S A (2017) 114:5247–52. doi: 10.1073/pnas.1702725114
10. Busnelli M, Saulière A, Manning M, Bouvier M, Galés C, Chini B. Functional selective oxytocin-derived agonists discriminate between individual G protein family subtypes. J Biol Chem (2012) 287:3617–299. doi: 10.1074/jbc.M111.277178
11. Smith MP, Ayad VJ, Mundell SJ, McArdle CA, Kelly E, López Bernal A. Internalization and desensitization of the oxytocin receptor is inhibited by Dynamin and clathrin mutants in human embryonic kidney 293 cells. Mol Endocrinol (2006) 20:379–88. doi: 10.1210/me.2005-0031
12. Yamamoto Y, Cushing BS, Kramer KM, Epperson PD, Hoffman GE, Carter CS. Neonatal manipulations of oxytocin alter expression of oxytocin and vasopressin immunoreactive cells in the paraventricular nucleus of the hypothalamus in a gender-specific manner. Neuroscience (2004) 125:947–55. doi: 10.1016/j.neuroscience.2004.02.028
13. Lee PR, Brady DL, Shapiro RA, Dorsa DM, Koenig JI. Prenatal stress generates deficits in rat social behavior: Reversal by oxytocin. Brain Res (2007) 1156:152–67. doi: 10.1016/j.brainres.2007.04.042
14. Freeman SM, Palumbo MC, Lawrence RH, Smith AL, Goodman MM, Bales KL. Effect of age and autism spectrum disorder on oxytocin receptor density in the human basal forebrain and midbrain. Transl Psychiatry (2018) 8:257. doi: 10.1038/s41398-018-0315-3
16. Leckman JF. Variations in maternal behavior--oxytocin and reward pathways--peripheral measures matter?! Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol (2011) 36:2587–2588. doi: 10.1038/npp.2011.201
18. Andari E, Duhamel J-R, Zalla T, Herbrecht E, Leboyer M, Sirigu A. Promoting social behavior with oxytocin in high-functioning autism spectrum disorders. Proc Natl Acad Sci U S A (2010) 107:4389–94. doi: 10.1073/pnas.0910249107
20. Strauss GP, Chapman HC, Keller WR, Koenig JI, Gold JM, Carpenter WT, et al. Endogenous oxytocin levels are associated with impaired social cognition and neurocognition in schizophrenia. J Psychiatr Res (2019) 112:38–43. doi: 10.1016/j.jpsychires.2019.02.017
21. Aydın O, Lysaker PH, Balıkçı K, Ünal-Aydın P, Esen-Danacı A. Associations of oxytocin and vasopressin plasma levels with neurocognitive, social cognitive and meta cognitive function in schizophrenia. Psychiatry Res (2018) 270:1010–6. doi: 10.1016/j.psychres.2018.03.048
22. Jansen LMC, Gispen-de Wied CC, Wiegant VM, Westenberg HGM, Lahuis BE, van Engeland H. Autonomic and neuroendocrine responses to a psychosocial stressor in adults with autistic spectrum disorder. J Autism Dev Disord (2006) 36:891–9. doi: 10.1007/s10803-006-0124-z
23. Jacobson JD, Ellerbeck KA, Kelly KA, Fleming KK, Jamison TR, Coffey CW, et al. Evidence for alterations in stimulatory G proteins and oxytocin levels in children with autism. Psychoneuroendocrinology (2014) 40:159–69. doi: 10.1016/j.psyneuen.2013.11.014
24. Scantamburlo G, Hansenne M, Fuchs S, Pitchot W, Maréchal P, Pequeux C, et al. Plasma oxytocin levels and anxiety in patients with major depression. Psychoneuroendocrinology (2007) 32:407–10. doi: 10.1016/j.psyneuen.2007.01.009
25. Parker KJ, Kenna HA, Zeitzer JM, Keller J, Blasey CM, Amico JA, et al. Preliminary evidence that plasma oxytocin levels are elevated in major depression. Psychiatry Res (2010) 178:359–62. doi: 10.1016/j.psychres.2009.09.017
26. Brandtzaeg OK, Johnsen E, Roberg-Larsen H, Seip KF, MacLean EL, Gesquiere LR, et al. Proteomics tools reveal startlingly high amounts of oxytocin in plasma and serum. Sci Rep (2016) 6:31693. doi: 10.1038/srep31693
27. Ross HE, Cole CD, Smith Y, Neumann ID, Landgraf R, Murphy AZ, et al. Characterization of the oxytocin system regulating affiliative behavior in female prairie voles. Neuroscience (2009) 162:892–903. doi: 10.1016/j.neuroscience.2009.05.055
28. King LB, Walum H, Inoue K, Eyrich NW, Young LJ. Variation in the oxytocin receptor gene predicts brain region-specific expression and social attachment. Biol Psychiatry (2016) 80:160–9. doi: 10.1016/j.biopsych.2015.12.008
29. Lee MR, Sheskier MB, Farokhnia M, Feng N, Marenco S, Lipska BK, et al. Oxytocin receptor mRNA expression in dorsolateral prefrontal cortex in major psychiatric disorders: a human post-mortem study. Psychoneuroendocrinology (2018) 96:143–7. doi: 10.1016/j.psyneuen.2018.05.039
30. Hansson AC, Koopmann A, Uhrig S, Bühler S, Domi E, Kiessling E, et al. Oxytocin reduces alcohol cue-reactivity in alcohol-dependent rats and humans. Neuropsychopharmacology (2018) 43:1235–46. doi: 10.1038/npp.2017.257
31. Lee MR, Schwandt ML, Sankar V, Suchankova P, Sun H, Leggio L. Effect of alcohol use disorder on oxytocin peptide and receptor mRNA expression in human brain: a post-mortem case-control study. Psychoneuroendocrinology (2017) 85:14–9. doi: 10.1016/j.psyneuen.2017.07.481
32. Uhrig S, Hirth N, Broccoli L, von Wilmsdorff M, Bauer M, Sommer C, et al. Reduced oxytocin receptor gene expression and binding sites in different brain regions in schizophrenia: a post-mortem study. Schizophr Res (2016) 177:59–66. doi: 10.1016/j.schres.2016.04.019
33. Harony-Nicolas H, Mamrut S, Brodsky L, Shahar-Gold H, Barki-Harrington L, Wagner S. Brain region-specific methylation in the promoter of the murine oxytocin receptor gene is involved in its expression regulation. Psychoneuroendocrinology (2014) 39:121–1. doi: 10.1016/j.psyneuen.2013.10.004
34. Maud C, Ryan J, McIntosh JE, Olsson CA. The role of oxytocin receptor gene (OXTR) DNA methylation (DNAm) in human social and emotional functioning: a systematic narrative review. BMC Psychiatry (2018) 18:154. doi: 10.1186/s12888-018-1740-9
35. Purba JS, Hoogendijk WJ, Hofman MA, Swaab DF. Increased number of vasopressin- and oxytocin-expressing neurons in the paraventricular nucleus of the hypothalamus in depression. Arch Gen Psychiatry (1996) 53:137–3. doi: 10.1001archpsyc.1996.01830020055007
37. Leppanen J, Ng KW, Tchanturia K, Treasure J. Meta-analysis of the effects of intranasal oxytocin on interpretation and expression of emotions. Neurosci Biobehav Rev (2017) 78:125–44. doi: 10.1016/j.neubiorev.2017.04.010
38. Wang D, Yan X, Li M, Ma Y. Neural substrates underlying the effects of oxytocin: a quantitative meta-analysis of pharmaco-imaging studies. Soc Cognit Affect Neurosci (2017) 12:1565–3. doi: 10.1093/scan/nsx085
39. Ooi YP, Weng S-J, Kossowsky J, Gerger H, Sung M. Oxytocin and Autism Spectrum Disorders: A systematic review and meta-analysis of randomized controlled trials. Pharmacopsychiatry (2017) 50:5–13. doi: 10.1055/s-0042-109400
40. Williams DR, Bürkner P-C. Effects of intranasal oxytocin on symptoms of schizophrenia: A multivariate Bayesian meta-analysis. Psychoneuroendocrinology (2017) 75:141–51. doi: 10.1016/j.psyneuen.2016.10.013
41. Bürkner P-C, Williams DR, Simmons TC, Woolley JD. Intranasal oxytocin may improve high-level social cognition in schizophrenia, but not social cognition or neurocognition in general: a multilevel bayesian meta-analysis. Schizophr Bull (2017) 43:1291–303. doi: 10.1093/schbul/sbx053
43. Labuschagne I, Poudel G, Kordsachia C, Wu Q, Thomson H, Georgiou-Karistianis N, et al. Oxytocin selectively modulates brain processing of disgust in Huntington’s disease gene carriers. Prog Neuropsychopharmacol Biol Psychiatry (2018) 81:11–6. doi: 10.1016/j.pnpbp.2017.09.023
44. Finger E, Berry S, Cummings J, Coleman K, Hsiung R, Feldman HH, et al. Adaptive crossover designs for assessment of symptomatic treatments targeting behaviour in neurodegenerative disease: a phase 2 clinical trial of intranasal oxytocin for frontotemporal dementia (FOXY). Alzheimers Res Ther (2018) 10:102. doi: 10.1186/s13195-018-0427-2
45. Jesso S, Morlog D, Ross S, Pell MD, Pasternak SH, Mitchell DGV, et al. The effects of oxytocin on social cognition and behaviour in frontotemporal dementia. Brain (2011) 134:2493–51. doi: 10.1093/brain/awr171
46. Grainger SA, Henry JD, Steinvik HR, Vanman EJ, Rendell PG, Labuschagne I. Intranasal oxytocin does not reduce age-related difficulties in social cognition. Horm Behav (2018) 99:25–34. doi: 10.1016/j.yhbeh.2018.01.009
48. Bales KL, Carter CS. Developmental exposure to oxytocin facilitates partner preferences in male prairie voles (Microtus ochrogaster). Behav Neurosci (2003) 117:854–9. doi: 10.1037/0735-7044.117.4.854
49. Hollander E, Bartz J, Chaplin W, Phillips A, Sumner J, Soorya L, et al. Oxytocin increases retention of social cognition in autism. Biol Psychiatry (2007) 61:498–503. doi: 10.1016/j.biopsych.2006.05.030
50. Pincus D, Kose S, Arana A, Johnson K, Morgan PS, Borckardt J, et al. Inverse effects of oxytocin on attributing mental activity to others in depressed and healthy subjects: a double-blind placebo controlled FMRI study. Front Psychiatry (2010) 1:134. doi: 10.3389/fpsyt.2010.00134
51. Guastella AJ, Ward PB, Hickie IB, Shahrestani S, Hodge MAR, Scott EM, et al. A single dose of oxytocin nasal spray improves higher-order social cognition in schizophrenia. Schizophr Res (2015) 168:628–33. doi: 10.1016/j.schres.2015.06.005
52. Hall SS, Lightbody AA, McCarthy BE, Parker KJ, Reiss AL. Effects of intranasal oxytocin on social anxiety in males with fragile X syndrome. Psychoneuroendocrinology (2012) 37:509–18. doi: 10.1016/j.psyneuen.2011.07.020
53. Quintana DS, Westlye LT, Rustan ØG, Tesli N, Poppy CL, Smevik H, et al. Low-dose oxytocin delivered intranasally with breath powered device affects social-cognitive behavior: a randomized four-way crossover trial with nasal cavity dimension assessment. Transl Psychiatry (2015) 5:e602. doi: 10.1038/tp.2015.93
54. Wynn JK, Green MF, Hellemann G, Reavis EA. Marder SR. A dose-finding study of oxytocin using neurophysiological measures of social processing. Neuropsychopharmacology (2019) 44:289–94. doi: 10.1038/s41386-018-0165-y
55. Brambilla M, Cotelli M, Manenti R, Dagani J, Sisti D, Rocchi M, et al. Oxytocin to modulate emotional processing in schizophrenia: a randomized, double-blind, cross-over clinical trial. Eur Neuropsychopharmacol (2016) 26:1619–28. doi: 10.1016/j.euroneuro.2016.08.001
56. Dagani J, Sisti D, Abelli M, Di Paolo L, Pini S, Raimondi S, et al. Do we need oxytocin to treat schizophrenia? A randomized clinical trial. Schizophr Res (2016) 172:158–64. doi: 10.1016/j.schres.2016.02.011
58. Suraev AS, Bowen MT, Ali SO, Hicks C, Ramos L, McGregor IS. Adolescent exposure to oxytocin, but not the selective oxytocin receptor agonist TGOT, increases social behavior and plasma oxytocin in adulthood. Horm Behav (2014) 65:488–96. doi: 10.1016/j.yhbeh.2014.03.002
61. Striepens N, Kendrick KM, Hanking V, Landgraf R, Wüllner U, Maier W, et al. Elevated cerebrospinal fluid and blood concentrations of oxytocin following its intranasal administration in humans. Sci Rep (2013) 3:3440. doi: 10.1038/srep03440
62. Dal Monte O, Noble PL, Turchi J, Cummins A, Averbeck BB. CSF and blood oxytocin concentration changes following intranasal delivery in macaque. PloS One (2014) 9:e103677. doi: 10.1371/journal.pone.0103677
63. Modi ME, Connor-Stroud F, Landgraf R, Young LJ, Parr LA. Aerosolized oxytocin increases cerebrospinal fluid oxytocin in rhesus macaques. Psychoneuroendocrinology (2014) 45:49–57. doi: 10.1016/j.psyneuen.2014.02.011
64. Neumann ID, Maloumby R, Beiderbeck DI, Lukas M, Landgraf R. Increased brain and plasma oxytocin after nasal and peripheral administration in rats and mice. Psychoneuroendocrinology (2013) 38:1985–93. doi: 10.1016/j.psyneuen.2013.03.003
65. Lee MR, Scheidweiler KB, Diao XX, Akhlaghi F, Cummins A, Huestis MA, et al. Oxytocin by intranasal and intravenous routes reaches the cerebrospinal fluid in rhesus macaques: determination using a novel oxytocin assay. Mol Psychiatry (2018) 23:115–22. doi: 10.1038/mp.2017.27
66. Beard R, Singh N, Grundschober C, Gee AD, Tate EW. High-yielding 18F radiosynthesis of a novel oxytocin receptor tracer, a probe for nose-to-brain oxytocin uptake in vivo. Chem Commun (Camb) (2018) 54:8120–3. doi: 10.1039/c8cc01400k
67. De Groot AN, Vree TB, Hekster YA, Pesman GJ, Sweep FC, Van Dongen PJ, et al. Bioavailability and pharmacokinetics of sublingual oxytocin in male volunteers. J Pharm Pharmacol (1995) 47:571–5. doi: 10.1111/j.2042-7158.1995.tb06716.x
68. Busnelli M, Dagani J, de Girolamo G, Balestrieri M, Pini S, Saviotti FM, et al. Unaltered oxytocin and vasopressin plasma levels in patients with schizophrenia after 4 months of daily treatment with intranasal oxytocin. J Neuroendocrinol (2016) 28:1–7. doi: 10.1111/jne.12359
69. Cai Q, Feng L, Yap KZ. Systematic review and meta-analysis of reported adverse events of long-term intranasal oxytocin treatment for autism spectrum disorder. Psychiatry Clin Neurosci (2018) 72:140–51. doi: 10.1111/pcn.12627
70. MacDonald E, Dadds MR, Brennan JL, Williams K, Levy F. Cauchi AJ. A review of safety, side-effects and subjective reactions to intranasal oxytocin in human research. Psychoneuroendocrinology (2011) 36:1114–26. doi: 10.1016/j.psyneuen.2011.02.015
71. Bakermans-Kranenburg MJ, van I Jzendoorn MH. Sniffing around oxytocin: review and meta-analyses of trials in healthy and clinical groups with implications for pharmacotherapy. Transl Psychiatry (2013) 3:e258. doi: 10.1038/tp.2013.34
72. Grace SA, Rossell SL, Heinrichs M, Kordsachia C, Labuschagne I. Oxytocin and brain activity in humans: a systematic review and coordinate-based meta-analysis of functional MRI studies. Psychoneuroendocrinology (2018) 96:6–24. doi: 10.1016/j.psyneuen.2018.05.031
73. Bethlehem RAI, van Honk J, Auyeung B, Baron-Cohen S. Oxytocin, brain physiology, and functional connectivity: a review of intranasal oxytocin fMRI studies. Psychoneuroendocrinology (2013) 38:962–74. doi: 10.1016/j.psyneuen.2012.10.011
74. Sabatier N, Caquineau C, Dayanithi G, Bull P, Douglas AJ, Guan XMM, et al. Alpha-melanocyte-stimulating hormone stimulates oxytocin release from the dendrites of hypothalamic neurons while inhibiting oxytocin release from their terminals in the neurohypophysis. J Neurosci (2003) 23:10351–8. doi: 10.1523JNEUROSCI.23-32-10351.2003
Keywords: oxytocin, social cognition, clinical trial, autism, schizophrenia, depression
Citation: Erdozain AM and Peñagarikano O (2020) Oxytocin as Treatment for Social Cognition, Not There Yet. Front. Psychiatry 10:930. doi: 10.3389/fpsyt.2019.00930
Received: 05 July 2019; Accepted: 22 November 2019;
Published: 09 January 2020.
Edited by:Philipp Kanske, Dresden University of Technology, Germany
Reviewed by:Izelle Labuschagne, Australian Catholic University, Australia
Lena Rademacher, Universität zu Lübeck, Germany
Copyright © 2020 Erdozain and Peñagarikano. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Olga Peñagarikano, firstname.lastname@example.org